Colon Cancer

Metastatic 1st or 2nd Line

A Multicenter, randomized, Open-Label Phase 3 Study of Encorafenib + Cetuximab +/- Binimetinib versus Irinotecan + Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E – mutant Metastatic Colorectal Cancer. Array-818-30

Metastatic 3rd or 4th Line

A Phase 2a Randomized, Open-Label Study to Access the Safety, Tolerability and Efficacy of BAX69 in Combination with 5-FU / Leucovorin or Panitumumab versus Standard of Care in Subjects with Metastatic Colorectal Cancer.  Baxalta 391401